DE69432752D1 - Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält - Google Patents

Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält

Info

Publication number
DE69432752D1
DE69432752D1 DE69432752T DE69432752T DE69432752D1 DE 69432752 D1 DE69432752 D1 DE 69432752D1 DE 69432752 T DE69432752 T DE 69432752T DE 69432752 T DE69432752 T DE 69432752T DE 69432752 D1 DE69432752 D1 DE 69432752D1
Authority
DE
Germany
Prior art keywords
progestogen
pct
estrogen
substitution therapy
oestrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432752T
Other languages
English (en)
Other versions
DE69432752T2 (de
Inventor
Robert Koninckx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saturnus AG
Original Assignee
Saturnus AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saturnus AG filed Critical Saturnus AG
Application granted granted Critical
Publication of DE69432752D1 publication Critical patent/DE69432752D1/de
Publication of DE69432752T2 publication Critical patent/DE69432752T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69432752T 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält Expired - Lifetime DE69432752T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL9301562 1993-09-09
NL9301562A NL9301562A (nl) 1993-09-09 1993-09-09 Preparaat voor substitutietherapie.
PCT/EP1994/002997 WO1995007081A1 (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one extrogen

Publications (2)

Publication Number Publication Date
DE69432752D1 true DE69432752D1 (de) 2003-07-03
DE69432752T2 DE69432752T2 (de) 2004-04-08

Family

ID=19862861

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432752T Expired - Lifetime DE69432752T2 (de) 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält

Country Status (12)

Country Link
US (1) US5827843A (de)
EP (1) EP0717626B1 (de)
JP (1) JPH09502194A (de)
KR (1) KR960704553A (de)
CN (1) CN1076969C (de)
AT (1) ATE241362T1 (de)
AU (1) AU708881B2 (de)
DE (1) DE69432752T2 (de)
FI (1) FI961098A (de)
HU (1) HU224818B1 (de)
NL (1) NL9301562A (de)
WO (1) WO1995007081A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
CA2261687A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
WO1998004246A2 (en) * 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
HRP20020666B1 (en) * 2000-01-18 2011-07-31 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
EE05533B1 (et) * 2000-01-18 2012-04-16 Schering Aktiengesellschaft Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
EP1857110A3 (de) * 2001-03-16 2008-08-06 Wyeth Hormonersatztherapie
HUP0303520A2 (hu) * 2001-03-16 2004-01-28 Wyeth Hormonpótlás biztosítására szolgáló eljárások és készítmények
CA2446849A1 (en) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
ES2278924T3 (es) * 2001-05-18 2007-08-16 Pantarhei Bioscience B.V. Composicion farmaceutica para el uso en terapia de sustitucion hormonal.
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
PT1390042E (pt) * 2001-05-23 2008-03-10 Pantarhei Bioscience Bv Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal
DE60234515D1 (de) * 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
EP1406634A1 (de) 2001-07-13 2004-04-14 Schering Aktiengesellschaft Kombination von drospirenon und estrogensulphamate-derivaten als hormon-replacement-therapie
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DK1446128T3 (da) * 2001-11-15 2007-04-02 Pantarhei Bioscience Bv Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
EP1453521B1 (de) 2001-12-05 2013-09-04 Teva Women's Health, Inc. Orale kontrazeptiva zum vermeiden der schwangerschaft und verminderung von praemenstruellen symptomen
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
ATE340579T1 (de) * 2002-06-11 2006-10-15 Pantarhei Bioscience Bv Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
EP1511498B1 (de) * 2002-06-11 2012-11-21 Pantarhei Bioscience B.V. Verfahren zur behandlung der menschlichen haut und hautpflegemittel zur verwendung in diesem verfahren
ES2299730T3 (es) * 2002-07-12 2008-06-01 Pantarhei Bioscience B.V. Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CN101001631B (zh) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US8236785B2 (en) * 2007-01-08 2012-08-07 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
ES2061672T3 (es) * 1987-09-24 1994-12-16 Jencap Research Ltd Preparado hormonal y su uso.
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product

Also Published As

Publication number Publication date
HU224818B1 (en) 2006-02-28
US5827843A (en) 1998-10-27
FI961098A0 (fi) 1996-03-08
FI961098A (fi) 1996-04-03
DE69432752T2 (de) 2004-04-08
WO1995007081A1 (en) 1995-03-16
HUT74452A (en) 1996-12-30
EP0717626A1 (de) 1996-06-26
AU708881B2 (en) 1999-08-12
CN1133011A (zh) 1996-10-09
EP0717626B1 (de) 2003-05-28
KR960704553A (ko) 1996-10-09
NL9301562A (nl) 1995-04-03
CN1076969C (zh) 2002-01-02
AU7695294A (en) 1995-03-27
ATE241362T1 (de) 2003-06-15
JPH09502194A (ja) 1997-03-04
HU9600592D0 (en) 1996-05-28

Similar Documents

Publication Publication Date Title
DE69432752D1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
IL111077A (en) Pyridine derivatives processes for the preparation thereof and pharmaceutical compositions containing them
TW285667B (de)
BR9407239A (pt) Azadioxacicloalquenos substituídos
IL151371A0 (en) Modified porcine factor viii and pharmaceutical compositions containing the same
DE69726577D1 (en) Kristallin form i von clarithromycin
MX9802130A (es) Agonistas adrenergicos beta3 selectivos.
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DK0733046T3 (da) Benzoylguanidiner, deres fremstilling og anvendelse i medikamenter
HK1002017A1 (en) Lyospheres comprising gonadotropin
CA2024188A1 (en) Method of treating premature ejaculation using sertraline
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
IL112059A0 (en) A transdermal therapeutic composition containing a deuterated active substance
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
AU695894B2 (en) Hormonal means for acne therapy and employment thereof
DE69109293D1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
CA2171460A1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
UA30722A (uk) Спосіб профілактики гнійно-септичних ускладнень у породіль
MD218C2 (ro) Stimulant pentru creşterea părului

Legal Events

Date Code Title Description
8364 No opposition during term of opposition